TytoCare Launches AI Care Enablement Platform and Unveils Tyto Health Hub™ to Manage High-Risk, High-Cost Patients at Home

Built on virtual care used by 240+ healthcare organizations and 1.6M+ patients, the modular platform starts with COPD and extends to cardiopulmonary conditions, including heart failure, as well as oncology and other serious illnesses.

NEW YORK, November 12, 2026 — TytoCare today launched its AI Care Enablement Platform and unveiled Tyto Health Hub™, a new AI-powered home companion with environmental sensing, conversational daily check-ins and step-by-step exam guidance. The platform extends TytoCare’s virtual care from episodic visits into longitudinal care management for patients with chronic and complex conditions. It combines remote exams, including FDA-cleared heart, lung and temperature exams [8], with third-party connected medical-grade devices, patient-reported outcomes and clinical AI, while consumer wearables add everyday context. The platform is designed to help care teams identify changes in a patient’s condition earlier and support timely intervention, with the goal of reducing avoidable emergency and inpatient care. 

“CMS just made the direction of healthcare unmistakable: more prevention, more accountable care and more responsibility for patients between visits,” said Adam Pellegrini, Chief Executive Officer of TytoCare. “Virtual care proved that clinical-grade care can happen anywhere. Now we’re bringing that foundation to the patients who need it most. Our AI Care Enablement Platform gives provider organizations a technology-enabled path to manage high-risk patients with their own care teams, at scale, and to succeed under value-based care. Automated workflows and AI-assisted patient prioritization enable clinicians to bring remote patient monitoring in-house and do more with the staff they already have, at a time when care teams are resource constrained.” 

Prominent health systems, provider organizations and national health plans, all existing TytoCare customers, have committed to roll out the platform, with the first patients enrolling by year-end. The launch follows TytoCare’s $25M+ growth round in July 2026, led by Insight Partners, and the appointment of Adam Pellegrini as CEO [2]. TytoCare also announced that Tania Elliott, MD, has joined its executive team as Chief Medical Officer. Dr. Elliott was previously Chief Medical Officer, Virtual Care, Clinical & Network Services at Ascension, where she advanced adoption of virtual visits and remote patient monitoring across the care continuum. 

“Having built virtual care inside a health system and a health plan, I’ve seen the same challenge every time: how to maintain visibility into high-risk patients and manage them effectively between visits,” said Dr. Elliott. “TytoCare helps solve that challenge with clinical-grade exams, AI-driven workflows and continuous data from the home. What excites me most is the chance to work with our provider, payer and partner organizations to turn proven virtual care practices into programs that reach every patient who needs them.” 

Built on a proven virtual care foundation 

TytoCare’s platform supports virtual-first care strategies. It serves 240+ healthcare organizations, 40,000+ providers and 1.6 million+ patients across 400,000+ homes and 10,000+ virtual and hybrid clinics [7], and it is already integrated into partners’ EMR systems and clinical workflows. 

Unlike standalone virtual care platforms, TytoCare adapts to the way each organization delivers care. Health plans can deploy it as a fully virtual solution for their members. Provider organizations can use it as an extension of their own practice, delivering seamless, integrated hybrid care that bridges the gap between office visits, with exam data and insights flowing back to the patient’s own care team. 

Many healthcare organizations have invested in point solutions for each condition or program, each with its own contract, staff training and data stream. The result is fragmented patient data, more work for care teams and a disjointed experience for patients. TytoCare enables organizations to run multiple chronic and complex care programs on one common, extensible platform to create a cohesive, continuous care experience for patients and care teams. 

Aligned with new Medicare policy 

On Nov. 4, CMS finalized the CY 2027 Medicare Physician Fee Schedule [1]. The rule raises evaluation and management payments, with larger increases for practitioners in accountable care organizations. It also sets a new direction for remote monitoring: beginning Jan. 1, 2029, Medicare is scheduled to pay for remote physiologic monitoring (RPM) only when it is furnished by clinical staff employed by the billing practice, not by outside contractors [1]. 

For provider organizations that rely on outsourced monitoring, the time to prepare is now. Bringing remote care in-house means new workflows, staffing models and technology, and it cannot be built overnight. TytoCare’s platform is designed to make that shift practical. Automated workflows, AI-assisted patient prioritization and integrated clinical dashboards help care teams manage more patients efficiently, creating a more complete model of care than outsourced monitoring alone. Organizations that need added capacity during the transition can add TytoCare clinical services. 

How it works 

• Assess: Remote exams of the heart, lungs, ears, throat, skin and temperature with TytoCare’s handheld exam device (heart, lung and temperature exams are FDA-cleared) [8], plus connected medical-grade devices, AI-guided patient-reported outcomes and consumer wearables that add everyday context. 

• Analyze: Clinical AI built on more than 7 million exams [7] highlights changes in each patient’s data over time for care-team review. FDA-cleared AI detection of wheezes, crackles and rhonchi [9] adds objective lung-sound findings to support clinical decisions. 

• Act: Patient trends and AI-assisted notifications appear in the Tyto Clinical Dashboard™ or the partner’s existing system. This helps care teams prioritize patients, allocate resources more efficiently and intervene sooner. 

The platform is condition-agnostic and device-agnostic, so organizations can run COPD, heart failure, other cardiopulmonary and oncology programs side by side on one modular platform. Its configurable design lets partners choose the service level, from technology only to a fully managed program. 

Introducing Tyto Health Hub™ 

Tyto Health Hub™ is the patient’s connection to the platform at home. It is designed to: 

• Sense the home environment with built-in environmental sensors that add context to each patient’s health data. 

• Check in and prioritize with AI, guiding patients through symptom check-ins based on care-team-defined protocols and helping care teams prioritize who needs attention first. 

• Engage patients daily with conversational check-ins, reminders and step-by-step guidance for remote exams. 

• Connect patients to their care team when follow-up is needed. 

Tyto Health Hub™ will be showcased at HLTH 2026 in Las Vegas [6] and is expected to be commercially available in the first half of 2027. 

Value for every organization that manages high-risk patients 

• Health systems extend clinician capacity, manage high-risk patients between visits and offer remote exams, not just video. 

• Health plans gain earlier visibility into high-risk members to support proactive care management, total cost of care and member experience. 

• Risk-bearing organizations manage rising-risk patients at home, with exam-grade data that supports quality and shared-savings performance. 

• Home health agencies escalate care without sending a clinician back and extend each nurse’s reach between visits. 

• Employers offer an exam-capable benefit that helps employees get care without unnecessary ER and urgent care visits. 

• Life sciences companies capture standardized, clinician-grade exam data between site visits and support patients on therapy at home. 

Clinical and economic value 

• 98% of TytoCare visits were resolved without an in-person follow-up appointment [3]. 

• TytoCare delivered 59% more accurate diagnoses than traditional audio/video telehealth [3]. 

• A Journal of Health Economics study of 28,000+ users found a 7% lower total cost of care and 24.1% lower ER utilization [4, 10]. 

• In a three-month comparative study, an integrated delivery network’s pediatric Medicaid program saw a 60% reduction in ED visits with TytoCare, compared with 7.9% for audio/video telehealth alone [5]. 

See it at HLTH 2026 

TytoCare will showcase the AI Care Enablement Platform and Tyto Health Hub™ at HLTH 2026 in Las Vegas, Nov. 15–18 [6]. To request an invitation to TytoCare’s private event, visit the event registration page. 

About TytoCare 

TytoCare is a virtual care and AI care enablement company that helps healthcare organizations deliver proactive, clinical-grade care at scale. The TytoCare AI Care Enablement Platform is built on FDA-cleared remote exam technology and clinical AI grounded in more than 7 million exams. It supports the full continuum of care, from virtual primary, urgent and specialty visits to longitudinal management of chronic, complex and high-risk patients. The modular, enterprise-grade platform unites remote exams, connected devices, patient engagement, clinical AI and care-team workflows into a continuous model of care. TytoCare serves more than 240 healthcare organizations and has reached more than 1.6 million patients. TytoCare is headquartered in New York and Netanya, Israel. Learn more at www.tytocare.com. 

Executive bios for Adam Pellegrini, Chief Executive Officer; Greg Orr, Chief Operating Officer; Carolyn Walsh, Chief Commercial Officer; and Tania Elliott, MD, Chief Medical Officer, are available in the TytoCare press kit at Press Kit 

Sources 

1. Medicare policy (CY 2027 Physician Fee Schedule final rule, Nov. 4, 2026; RPM/RTM employed-staff requirement delayed to Jan. 1, 2029): CMS fact sheet; American Hospital Association summary. 

2. $25M+ growth round led by Insight Partners and CEO appointment (July 15, 2026): HIT Consultant; FinSMEs. 

3. 98% of visits resolved without in-person follow-up; 59% more accurate diagnoses than audio/video telehealth: TytoCare press release, June 4, 2024; “Driving Growth Together: Demonstrating TytoCare’s Business Impact on Partners” (2023). 

4. Journal of Health Economics study (28,213 users; 7% lower total cost of care; 24.1% lower ER utilization): TytoCare press release, July 12, 2023; “Adoption and Utilization of Device-Assisted Telemedicine” study summary. 

5. Pediatric Medicaid IDN study (60% vs. 7.9% reduction in ED visits): TytoCare report, 2022 (PDF). 

6. HLTH 2026 (Nov. 15–18, The Venetian Expo, Las Vegas): HLTH USA 2026. 

7. Company metrics (240+ healthcare organizations, 40,000+ providers, 1.6M+ patients, 7M+ exams): TytoCare.com. 

8. FDA 510(k) clearances for Tyto Stethoscope and Tyto Thermometer (K252089, K190242): FDA 510(k) database. 

9. FDA 510(k) clearances for Tyto Insights wheeze, crackle and rhonchi detection (K232237, K240555, K243567): FDA 510(k) database. 

10. Zeltzer D, Einav L, Rashba J, Waisman Y, Haimi M, Balicer RD. Adoption and utilization of device-assisted telemedicine. Journal of Health Economics. 2023;90:102780. doi:10.1016/j.jhealeco.2023.102780. 

Media contact 
Carolyn Walsh 
Chief Commercial Officer, TytoCare 
Carolyn.Walsh@tytocare.com